Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 7/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | ADH1A | P07327 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | ABL2 | P42684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13311266 | 0.95 | HRH4 (0.40) | HRH4HRH3HRH1SYK | |
| SCHEMBL16299920 | 0.93 | HRH4 (0.40) | HRH4HRH3HRH1SYKMMP13 | |
| SCHEMBL13311170 | 0.91 | SYK (0.36) | HRH4HRH3HRH1SYK | |
| SCHEMBL13007046 | 0.91 | HRH4 (0.51) | HRH4HRH3HRH1ADH1AKIT | |
| SCHEMBL13805711 | 0.91 | HRH4 (0.40) | HRH4HRH3HRH1SYK | |
| SCHEMBL14586775 | 0.91 | HRH4 (0.44) | HRH4 | |
| SCHEMBL18584155 | 0.91 | HRH4 (0.39) | HRH4HRH3HRH1SYK | |
| SCHEMBL10085051 | 0.90 | HRH4 (0.40) | HRH4HRH3HRH1SYK | |
| SCHEMBL12251617 | 0.90 | HRH4 (0.40) | HRH4HRH3HRH1SYK | |
| SCHEMBL10111775 | 0.90 | MMP13 (0.42) | SYKMMP13ADH1AKITFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027782-A1 | MONOCLONAL ANTIBODY PARTNER MOLECULE CONJUGATES DIRECTED TO PROTEIN TYROSINE KINASE 7 (PTK7) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027782-A1 | MONOCLONAL ANTIBODY PARTNER MOLECULE CONJUGATES DIRECTED TO PROTEIN TYROSINE KINASE 7 (PTK7) | PTK2, PTK2B, LTK | HRH4 3539/4885HRH3 2519/4885HRH1 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.